This Plain Language Summary of Publication article (PLSP) from Future Oncology, highlights the results of the CheckMate 901 trial, which investigated advanced urothelial cancer that is either unresectable or metastatic. Researchers evaluated whether combining nivolumab, an immunotherapy drug, with chemotherapy was more effective and durable than chemotherapy alone. Urothelial cancer typically affects the urinary system, and this trial aimed to explore improved treatment options for cases where surgery is not possible or the cancer has spread.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Nivolumab plus Gemcitabine–Cisplatin
in Advanced Urothelial Carcinoma’ and was published in the New England Journal of Medicine.

Visit NEJM using the link to read the original article.